Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model
Abstract
Metformin treatment improved ADPKD disease severity in a relevant, slowly progressive ADPKD mouse model that recapitulates a PKD-associated PKD1 mutation. Relative to controls, metformin reduced kidney weight/body weight, cystic index and BUN levels, while improving GFR, blood pressure and anemia. Metformin also reduced key inflammatory and injury markers, along with cell proliferation markers. These findings suggest several beneficial effects of metformin in this ADPKD mouse model, which may help inform new ADPKD therapies in patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2022
- Source ID
- 10.1152/ajprenal.00298.2021
Entities
People
- Biagio Saitta
- Daniel Rivera
- Hui Li
- Jessica Pham
- Kenneth Hallows
- Núria M. Pastor-soler
- Pei-yin Ho
- Valeria Mancino
Organizations
- United States Department of Defense
- University of Southern California